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ORIGINAL ARTICLE
Next-generation sequencing with a myeloid gene panel in
core-binding factor AML showed KIT activation loop and
TET2 mutations predictive of outcome
CY Cher1,12, GMK Leung1,12, CH Au2,12, TL Chan2, ESK Ma2, JPY Sim1, H Gill1, AKW Lie1, R Liang3, KF Wong4, LLP Siu4, CSP Tsui5, CC So5,
HWW Wong1, SF Yip6, HKK Lee7, HSY Liu8, JSM Lau9, TH Luk9, CK Lau10, SY Lin11, YL Kwong1 and AYH Leung1 on behalf of the
Hong Kong AML Study Group
Clinical outcome and mutations of 96 core-binding factor acute myeloid leukemia (AML) patients 18–60 years old were examined.
Complete remission (CR) after induction was 94.6%. There was no signiﬁcant difference in CR, leukemia-free-survival (LFS) and
overall survival (OS) between t(8;21) (N= 67) and inv(16) patients (N= 29). Univariate analysis showed hematopoietic stem cell
transplantation at CR1 as the only clinical parameter associated with superior LFS. Next-generation sequencing based on a myeloid
gene panel was performed in 72 patients. Mutations in genes involved in cell signaling were associated with inferior LFS and OS,
whereas those in genes involved in DNA methylation were associated with inferior LFS. KIT activation loop (AL) mutations occurred
in 25 patients, and were associated with inferior LFS (P= 0.003) and OS (P= 0.001). TET2 mutations occurred in 8 patients, and were
associated with signiﬁcantly shorter LFS (P= 0.015) but not OS. Patients negative for KIT-AL and TET2 mutations (N= 41) had
signiﬁcantly better LFS (Po0.001) and OS (P= 0.012) than those positive for both or either mutation. Multivariate analysis showed
that KIT-AL and TET2 mutations were associated with inferior LFS, whereas age ⩾ 40 years and marrow blast ⩾ 70% were associated
with inferior OS. These observations provide new insights that may guide better treatment for this AML subtype.
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INTRODUCTION
Acute myeloid leukemia (AML) is a group of heterogeneous
diseases with distinct clinicopathologic, cytogenetic and genetic
characteristics. Conventional therapeutic approaches include
induction and consolidation chemotherapy. Patients at high risk
of relapse receive allogeneic hematopoietic stem cell transplanta-
tion (HSCT) as post-remission therapy. AMLs with translocation
involving core-binding factors (CBF) including t(8;21)(q22;q22) and
inv(16)(p13;q22) or t(16;16)(p13;q22) constitute a distinct clinico-
pathologic subtype as deﬁned by the World Health Organization
(WHO), and occur in 15–20% of adult patients.1,2 In general, CBF-
AML has a superior outcome compared with other cytogenetic
subtypes, with a long-term overall survival (OS) of 40–60%.3–7
However, their clinical outcome is highly heterogeneous. Muta-
tions of type III receptor tyrosine kinase KIT in the activation loop
at exon 17 (D816, N822) and the extracellular domain at exon
8, which are rare in other AMLs, occurred in 12–46% cases of
t(8;21) and 9–53% of cases of inv(16).8–15 These mutations may
induce ligand-independent KIT activation and are generally
associated with a higher risk of relapse and poorer prognosis.
The impacts of other gene mutations frequently identiﬁed in AML,
including RAS and FLT3, on outcome in these AML are less well
deﬁned. With the advent of next-generation sequencing (NGS),
the genomic landscape of AML can be examined in detail. In
particular, The Cancer Genome Atlas (TCGA) examined the
genomic proﬁle of 200 de novo AML and provided important
genomic information of this disease.16 However, the number of
CBF-AML in TCGA was limited.
In this study, we examined the clinical outcome of a consecutive
cohort of patients with CBF-AML who were treated with a uniform
approach and examined their mutation spectrum using NGS. The
aim was to deﬁne the clinicopathologic characteristics and identify
novel gene mutations of prognostic values for the design of better
therapeutic strategies in this AML subtype.
MATERIALS AND METHODS
Patients
Consecutive patients aged 18–60 years, diagnosed with t(8;21)(q22;q22) or
inv(16)(p13;q22) CBF-AML in six regional hospitals in Hong Kong between
January 2003 and December 2015, were retrospectively analyzed. The
diagnoses were conﬁrmed by ﬂuorescence in situ hybridization or reverse
transcription-PCR for RUNX1/RUNX1T1 and CBFB/MYH11 fusions. All patient
records were retrieved and independently reviewed by two investigators.
Clinicopathologic features, including age, gender, presenting white cell
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counts, marrow blast percentage, additional cytogenetic abnormalities,
induction and consolidation regimens, HSCT and the source of HSC, were
analyzed. The study was approved by the institutional review boards
of Hospital Authority (HKU/HA HKW UW14-430; KC/KE-15-0039/ER-3;
KW/EX-15-052/85-05; NTWC/CREC/15013) and research ethics committee
of Hong Kong Sanatorium & Hospital (REC-2015-02).
Treatments
Speciﬁc chemotherapy regimens are shown in Supplementary Table S1.
Induction chemotherapy comprised daunorubicin and cytarabine. Reas-
sessment bone marrow was performed between days 21 and 28 after
induction. Consolidation comprised four courses of high-dose cytarabine.
Before 2012, two courses of daunorubicin and etoposide were given as
consolidation before high-dose cytarabine. Remission and relapse were
deﬁned by standard criteria. Salvage chemotherapy included ICE
(idarubicin, cytarabine, etoposide), MAC (mitoxantrone, cytarabine), FLAG
(ﬂudarabine, cytarabine, granulocyte-colony stimulating factor) and CLARA
(clofarabine, cytarabine). Patients who achieved second complete remis-
sion (CR2) received the same salvage chemotherapy as consolidation until
HSCT or leukemic progression (Supplementary Table S2).
Allogeneic hematopoietic stem cell transplantation
Indications of HSCT at CR1 for eligible patients included two or more
inductions to achieve CR1, additional chromosomal abnormalities and
presence of KIT mutations. HSCT was recommended for all eligible patients
in CR2. Allogeneic HSCT was performed in Queen Mary Hospital. Bu-Cy
(busulfan; cyclophosphamide) was employed as myeloablative condition-
ing, and Flu-Bu (ﬂudarabine, busulfan) and Cy-TBI (total body irradiation)
for non-myeloablative conditioning. Patients received standard antimicro-
bial and graft versus host disease prophylaxis as described previously.17
Patients who relapsed after HSCT received one of the salvage regimens
aforementioned followed by infusion of mobilized peripheral blood
HSC from the original donors.18
Next-generation sequencing
Diagnostic bone marrow samples were collected. DNA was extracted using
the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) and analyzed
by MiSeq NGS with the TruSight Myeloid sequencing panel (Illumina,
San Diego, CA, USA). The panel targeted 54 genes covering full coding
sequence of 15 genes and exonic hot spot for 39 genes (Supplementary
Table S3). Workﬂows of MiSeq sequencing library preparation, variant
calling and annotation as well as detection of FLT3 internal tandem
duplication by ITDseek has been previously described.19 Complex
insertions and deletions were detected by an in-house designed algorithm
INDELseek on a Cray XC30 supercomputer (Cray Inc., Seattle, WA, USA).
Figure 1. Treatment outcome of 96 CBF-AML patients in this study. Outcome of HSCT has been described in the text. FU, follow-up; NR,
nonremission; R1, ﬁrst relapse; R2, second relapse.
Table 1. Clinicopathologic characteristics of 96 patients with CBF-AML
Features Number (%)
Gender
Male 53 (55.2%)
Female 43(44.8%)
Age (median, range) (years) 41 (18–60)
Presenting WCC (median, range) (×109/l) 16.4 (1.6–396.6)
BM blast % (median, range) 50 (20–100)
CBF-AML
t(8;21) 67 (69.8%)
inv(16) 29 (30.2%)
Other cytogenetic abnormalities
Sole 31 (32.3%)
Additionala 65 (67.7%)
Induction to achieve CR1b
One 73 (83.0%)
4One 15 (17.0%)
First salvage chemotherapy
ICE 1
FLAG 1
MAC 7
Second course of 7+3 6
HSCT 42 (43.8%)
Status at HSCT
CR1 14
CR2 25
4CR2 2
R1 1
Source of HSC
Sibling 24
Matched unrelated donor 18
No HSCT 54 (56.3%)
Abbreviations: AML, acutemyeloid leukemia; BM, bonemarrow; CBF, core-binding
factor; CR1, ﬁrst complete remission; CR2, second complete remission; FLAG,
ﬂudarabine, cytarabine, granulocyte-colony stimulating factor; HSCT, hematopoie-
tic stem cell transplantation; ICE, idarubicin, cytarabine, etoposide; MAC,
mitoxantrone, cytarabine; R1, ﬁrst relapse; WCC, white cell count; 7:3, cytarabine,
daunorubicin. aAdditional chromosomal abnormalities included trisomy-X (n=10),
trisomy-Y (n=24) and others (n=31). bA total of 88 patients achieved CR1.
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Orthogonal validation of detected variants
Mutations with variant allele frequency (VAF) o20% were conﬁrmed by one
of the following methods according to the speciﬁc gene mutations involved.
These included microﬂuidic PCR using Access Array 48.48 (Fluidigm, South
San Francisco, CA, USA) and a different primer panel followed by MiSeq NGS,
bi-directional Sanger sequencing or PCR fragment analysis by capillary
electrophoresis using ABI 3130xl genetic analyzer (Applied Biosystems, Foster
City, CA, USA). Only conﬁrmed variants were analyzed in this study.
Survival and statistical analyses
Leukemia-free survival (LFS) was deﬁned as the time between ﬁrst
complete remission (CR1) to ﬁrst relapse. Unless otherwise speciﬁed, LFS
was censored at the date of the last follow-up or death. Overall survival
(OS) was deﬁned as the time between diagnosis and death or the date of
the last follow up. Treatment-related mortality was deﬁned as death within
30 days of the last chemotherapy or HSCT. Numerical data were compared
using Mann–Whitney U-test for nonparametric and Student’s t-test for
parametric parameters. Categorical data were compared using χ2 test.
Different thresholds for age (increment of 10 years, from 20 to 50 years),
white cell counts (increments of 10 × 109/l, from 10 to 100× 109/l) and
marrow blasts percentage (increment of 10%, from 30 to 90%) were tested
to identify the optimal cutoffs that best deﬁned LFS and OS. Parameters
that fulﬁlled the proportional hazard assumption with a P-valueo0.1 in
univariate analyses were further evaluated by multivariate analysis with the
Cox proportional hazards model. Survival curves were constructed using
the Kaplan–Meier method and compared by the log-rank test. All analyses
were performed using SPSS (IBM Corp., Armonk, NY, USA). A P-value of 0.05
was considered statistically signiﬁcant.
Figure 2. Mutational spectrum and its impact on 72 CBF-AML patients. (a) Each column represented data from a single CBF-AML patient.
Genetic mutation is colored in purple, t(8;21) in green and inv(16) in blue. (b) Survival impacts of mutations of genes involved in cell signaling.
(c) Survival impacts of mutations of genes involved in DNA methylation.
KIT-AL and TET2 mutations predict outcome in CBF-AML
CY Cher et al
3
Blood Cancer Journal
RESULTS
Clinicopathologic characteristics and induction chemotherapy
During the study period, 96 patients with CBF-AML were
diagnosed. Of these patients, 91 received a standard 7-day
regimen of cytarabine (100 mg/m2/day) and 3-day regimen of
daunorubicin (50 mg/m2, N= 72; 90 mg/m2, N= 18; not speciﬁed,
N= 1). One patient received 5:2, and one patient received MAC.
Three patients did not receive chemotherapy (Figure 1 and
Supplementary Table S2). All 96 patients were included in the
survival analysis.
Treatment outcome
Out of 93 patients, 88 (94.6%) achieved CR1 after one (N = 73),
two (N = 10), three (N = 4) and four (N = 1) courses of induction.
Five patients died of refractory leukemia. There was no
signiﬁcant difference in CR rates between AML with t(8;21)
and inv(16) (95.5% versus 92.6%, P = 0.579), and they had similar
LFS and OS (Supplementary Figure S1). Fourteen patients
received HSCT at CR1, of whom 8 had remained in remission
after a median follow-up of 83.8 (44.6–151.3) months. For 74
patients not receiving HSCT at CR1, 22 had remained in
remission after a median follow-up of 27.1(4.4–121.6) months.
A total of 52 patients had relapsed at a median of 8.9 (1–25.6)
months from CR1. Of these patients, 49 received reinduction
chemotherapy including MAC (N = 22), FLAG (N = 9), ICE (N = 7),
7:3 (N = 4), CLARA (N = 2) and others (N = 5). Thirty-six patients
(73.5%) achieved CR2. Of these patients, 25 underwent
allogeneic HSCT at CR2, of whom 13 (52%) had remained in
remission after a median follow-up of 67.0 (26.5–137.5) months,
10 (40%) had relapsed at a median of 4.9 (1.6–37.8) months post
HSCT and 2 had died of transplant-related mortality. For the
other 11 CR2 patients not receiving HSCT, 6 had relapsed at a
median of 6.6 (5.4–7.8) months from CR2; 3 had remained in
remission 52.6 (2.5–107.4) months from CR2; and 2 had been lost
to follow-up (Table 1).
Mutational analysis
Genomic studies based on NGS of a myeloid gene panel were
carried out in 72 patients, of whom 70 had received induction
chemotherapy. When genes were categorized into functional
groups, the most common mutations were those involved in cell
signaling (N= 60), chromatin modiﬁcation (N= 15), DNA methyla-
tion (N= 10), cohesin complex (N= 10), RNA splicing (N= 6), tumor
suppression (N=5) and transcription (N=5) (Supplementary Table S4).
Six patients had no mutations and 36 patients showed two or
more mutations. The most common recurrent mutations occurred
in KIT (N= 37, 51.4%), RAS (HRAS= 1; KRAS= 3; NRAS= 13; overall:
23.6%) and TET2 (N= 8, 11.1%). Other recurrent mutations
included FLT3 (N= 7, 9.7%) and RAD21 (N= 7, 9.7%) (Figure 2a
and Supplementary Figure S2A). The nature of these mutations is
shown in Supplementary Table S5.
Functional group analysis
To overview the mutation spectrum and to provide mechanistic
insights into the pathogenesis of CBF-AML, we evaluated the
impact of gene mutations, categorized into speciﬁc functional
groups, on LFS and OS. Gene mutations involved in molecular
pathways of cell signaling were associated with inferior LFS and
OS (Figure 2b). Gene mutations involved in DNA methylation were
associated with inferior LFS but not OS (Figure 2c). Mutations in
other functional groups have no signiﬁcant impact on either
LFS or OS. Importantly, patients negative for gene mutations in
both signaling and DNA methylation, compared with those
positive for either or both mutations, had signiﬁcantly superior
10-year LFS (75.0% versus 17.9%, P= 0.007) and 10-year OS
(83.3% versus 36.1%, P= 0.039) (Figure 3).
KIT mutations
KIT mutations were identiﬁed in 29 patients with t(8;21) and
8 patients with inv(16). Mutation locations are shown in Figure 4a,
being most prevalent in exon 17 (N= 26, D816 and N822 occurring
at the activation loop (AL) of the tyrosine kinase domain) and exon
8 (N= 13), with others scattered in exons 9, 10, 11 and 12. Seven
patients had two or more mutations. AL mutations, when
compared with non-AL mutations, were associated with signiﬁ-
cantly higher median VAF (42% versus 12%, P= 0.001), compar-
able median presenting white cell counts (11.7 × 109 versus
20× 109/l, P= 0.100) and CR rates (88% versus 97.8%, P= 0.136),
but inferior LFS (P= 0.022) and OS (P= 0.003) (Supplementary
Figure S2B). When patients with non-AL mutations were
compared with patients without the mutations, LFS and OS were
similar (Supplementary Figure S2C). Therefore, patients with
AL mutations, when compared with patients having non-AL or
no mutations, had signiﬁcantly inferior LFS (P= 0.003) and
OS (P= 0.001) (Figure 4b).
TET2 mutations
TET2 mutations, being distributed throughout the coding
sequence, were found in eight patients (Figure 4c). All but one
patients had VAF440% (median: 43%, range: 16–53%), and three
patients had two or more mutations. Patients with mutations,
when compared with patients without mutations, showed a
signiﬁcantly shorter LFS but comparable OS (Figure 4d).
Figure 3. Impacts of gene mutations in cell signaling and DNA
methylation on LFS and OS.
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Other mutations
Mutations in RAS (median VAF: 33%, range: 10–77%), FLT3 (median
VAF: 5%, range: 1–53%) and RAD21 (median VAF: 25%, range
16–46%) did not affect LFS or OS (Supplementary Figures S3A–C).
KIT-AL and TET2 double mutations
As KIT-AL and TET2 mutations were associated with an inferior
outcome, the impact of combined KIT-AL and TET2 mutations was
examined. Patients were divided into two groups. Group 1
comprised patients negative for KIT-AL mutations (including
wild-type KIT and non-AL KIT mutations) and TET2 mutations
(double negative, N= 41). Group 2 comprised patients with either
one or both of KIT-AL and TET2 mutations (N= 31). Group 1
compared with group 2 patients had similar CR rates (97.4%
versus 90.3%, P= 0.20), but signiﬁcantly superior 10-year LFS
(35.6% versus 11.9%, Po0.001) and 10-year OS (52.6% versus
28.3%, P= 0.012) (Figure 5a).
Impact of allogeneic HSCT
Patients undergoing HSCT in CR1, when compared with those
without, had signiﬁcantly better LFS (P= 0.004) but similar OS
(Figure 5b). The impact of HSCT in CR1 for each genetic subgroup
was not evaluated because of the small patient number in each
category. HSCT from HLA-identical sibling donors or matched
unrelated donors showed comparable LFS and OS (Supplementary
Figure S4).
Figure 4. KIT and TET2 mutations in CBF-AML. (a) Mutations in KIT were concentrated at the AL in exon 17 as shown. Other mutations were
scattered in different exons. (b) Kaplan–Meier analyses showing that KIT-AL mutations were associated with inferior LFS and OS. (c) Mutations
in TET2 were scattered throughout the coding sequence. (d) Kaplan–Meier analyses showing that TET2 mutations were associated with inferior
LFS but not OS (right panel).
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Prognostic factors
Univariate analysis showed that HSCT at CR1 was signiﬁcantly
associated with better LFS. Mutations in cell signaling and DNA
methylation as functional groups and KIT-AL and TET2 mutations
as individual genes were signiﬁcantly associated with inferior LFS
(Table 2). Age ⩾ 40 years, presenting white blood cell count
⩾ 100× 109/l and marrow blasts ⩾ 70% were signiﬁcantly asso-
ciated with inferior OS. Mutations in cell signaling and KIT-AL were
also associated with an inferior OS. Multivariate analysis showed
that KIT-AL and TET2 mutations were signiﬁcant adverse factors for
LFS, whereas age ⩾ 40 years and marrow blast ⩾ 70% were
adverse factors for OS. An adverse indicator for OS in univariate
analysis notwithstanding, KIT-AL mutation did not fulﬁll the
proportional hazard assumption and was excluded from multi-
variate analysis.
DISCUSSION
Patients with CBF-AML are clinically heterogeneous despite similar
cytogenetic aberrations, implying that secondary mutations might
be pathogenetically important. In fact, mutations involving KIT,
FLT3 and RAS were commonly reported in CBF-AML.8,10,11,20
Knock-in mouse models of RUNX1/RUNX1T1 or CBFB/MYH11
induced a preleukemia hematopoietic state and required addi-
tional mutations for the development of AML,21,22 supporting the
proposition of a ‘second-hit’ leukemogenic model. With NGS, a
recent study recruiting both adult and pediatric patients from two
clinical trials has identiﬁed mutations in cell signaling, cohesion
complex and chromatin modiﬁcation, being associated with
higher risk of relapse.14
In this study, we examined the mutation spectrum in CBF-AML
and the clinicopathologic features of an exclusively adult patient
population who were treated with a uniform algorithm. Mutations
of genes involved in cell signaling were associated with
signiﬁcantly inferior LFS and OS, whereas those in DNA methyla-
tion were associated with a signiﬁcantly inferior LFS. Remarkably,
patients without any mutations in genes involved in cell signaling
and DNA methylation had long-term LFS and OS of ∼ 80%. The
identity of genes in these categories was diverse, with KIT and
TET2 being the most common. Other functional groups had no
impact on clinical outcome. These results underscore the genetic
heterogeneity in CBF-AML, and provide clinical evidence for the
importance of concomitant mutations in these leukemias.
In this study, KIT mutations were identiﬁed in 450% of tested
patients, with KIT-AL mutations in 35% of them. The prevalence
was comparable with those reported based on targeted
sequencing.9,10 Importantly, only KIT-AL mutations but not other
mutations were associated with inferior LFS and OS. Over-
expression of KIT-AL mutant has been shown to cooperate with
RUNX1-RUNX1T1 or CBFB-MYH11 to induce AML in mice.21,22
However, KIT mutations are known to be unstable during disease
evolution, with nearly 50% of cases losing or changing their
mutations at relapse.10 The mechanistic link between KIT-AL
mutations and inferior prognosis in CBF-AML would have to be
further elucidated.
Figure 5. Impacts of KIT-AL and TET2mutations and HSCT at CR1. (a) Kaplan–Meier analyses showing that patients who were negative for both
KIT-AL and TET2mutations had superior LFS and OS compared with those who were positive for either or both of these mutations. (b) Kaplan–
Meier analyses showing that patients receiving HSCT at CR1 were associated with superior LFS but not OS.
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We also showed for the ﬁrst time that TET2 mutations were an
adverse prognostic factor in CBF-AML. Earlier studies examining TET2
mutations with bidirectional Sanger sequencing or 454-based NGS
failed to detect any TET2 mutations in CBF-AML.23,24 Of AML cases
examined in TCGA, mutation in TET2 was shown in only 1 of 7 cases
with t(8;21), and none of 11 cases with inv(16).16 A more recent study
based on RNA-sequencing has shown TET2 mutations in 3 of 20
cases with t(8;21), but none in 28 cases with inv(16).15 In this study,
we have shown a similar frequency (6/51) of TET2mutations in t(8;21)
and an apparently higher frequency (2/21) in inv(16). The scattering
of mutations throughout the coding sequence and the lack of hot
spot mutations supported the proposition that they were loss-of-
function mutations. In all patients but one, TET2 mutations had VAF
440%, suggesting that the TET2-mutant clone was predominant and
occurred in a heterozygous state. TET2 functions as a dioxygenase
that converts 5 methylcytosine to 5 hydroxymethylcytosine, with a
pivotal role in DNA demethylation.25 In mice, loss of TET2 has been
shown to induce genome-wide enhancer methylation that in a CBF-
AML model collaborates to induce an aggressive leukemia.26,27
Further studies are needed to validate the very poor prognostic
impact and deﬁne the pathogenetic/mechanistic basis of concomi-
tant KIT-AL and TET2 mutations.
In our CBF-AML patients not receiving allogeneic HSCT in CR1, the
poor long-term LFS of only 20–30% (Supplementary Figure S5) was
comparable with the results from an earlier report on t(8;21) AML from
our center28 and other reports from Asia,29,30 but inferior to results
reported from larger international studies.31,32 It is unclear whether the
inferior results of chemotherapy in our patients were because of a
different gene mutation spectrum, the small size of this cohort or a
difference in treatment regimens. However, the long-term OS was
similar to that reported previously,5 supporting the notion that
relapsed CBF-AML remained sensitive to salvage chemotherapy and
patients could still be rescued by allogeneic HSCT.
Because relapsed patients are still salvageable, it remains
uncertain whether frontline allogeneic HSCT is needed for CBF-
AML. Accordingly, we showed an improved LFS but not OS in our
patients receiving allogeneic HSCT in CR1, consistent with results
from other studies employing frontline HSCT in CBF-AML, either
because of institute policy or guided by minimal residual
leukemia.29,30,33 With improvement in supportive care and advent
of reduced-intensity, the indications and potential beneﬁt of
upfront HSCT for selected CBF-AML patients, particularly those
with unfavorable gene mutation proﬁles, should be explored.
Our observations have important clinical implications. Patients
without KIT-AL and TET2 mutations (‘double-negative’ patients) have
favorable outcome, suggesting this to be a distinct genetic subgroup
that may be curable with chemotherapy. In fact, patients without any
mutations involved in cell signaling (which included KIT-AL mutations)
and DNA methylation (which included TET2 mutations) had an even
more favorable LFS and OS. With the decreasing cost of NGS, a more
extensive examination of genetic mutations at diagnosis may become
a plausible strategy for prognostication. Furthermore, minimal residual
disease monitoring has been shown to predict treatment outcome
and provide guidance to HSCT indication in CBF-AML.33–37 Treatment
algorithms incorporating mutational proﬁles and minimal residual
disease monitoring should be tested to deﬁne whether better risk
stratiﬁcation may be achieved in this AML subtype.
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Table 2. Univariate and multivariate analysis of leukemia-free survival (LFS) and overall survival (OS)
LFS OS
P-value Hazard ratio 95% CI P-value Hazard ratio 95% CI
Lower Upper Lower Upper
Univariate analysis
Male gender 0.977 0.99 0.59 1.67 0.448 1.27 0.68 2.38
Age ⩾ 40 years 0.807 1.07 0.63 1.80 0.013 2.31 1.20 4.48
WCC ⩾ 100× 109/l 0.557 1.54 0.37 6.42 0.010 5.04 1.46 17.37
BM blasts ⩾ 70% 0.762 0.91 0.48 1.72 0.010 2.43 1.23 4.79
41 induction to CR1 0.584 0.82 0.40 1.68 0.299 1.50 0.70 3.21
HSCT at CR1 0.006 0.28 0.11 0.70 0.246 0.60 0.25 1.43
Mutations in signaling 0.020 3.42 1.22 9.63 0.047 4.26 1.02 17.80
Mutations in methylation 0.030 2.26 1.08 4.72 0.940 0.96 0.37 2.50
KIT-AL 0.004 2.46 1.33 4.55 0.001 3.09 1.56 6.12
TET2 0.019 2.64 1.17 5.97 0.996 1.00 0.35 2.85
RAS 0.785 0.91 0.45 1.84 0.804 0.90 0.41 2.00
FLT3 0.664 0.80 0.28 2.23 0.966 0.98 0.30 3.19
RAD21 0.284 0.57 0.20 1.60 0.406 0.61 0.18 1.98
KIT-ALNeg and TET2Neg 0.001 0.35 0.19 0.65 0.015 0.43 0.22 0.85
Multivariate analysis
Age ⩾ 40 years – – – – 0.013 2.36 1.19 4.65
WCC ⩾ 100× 109/l – – – – 0.109 2.90 0.79 10.65
BM blasts ⩾ 70% – – – – 0.036 2.16 1.05 4.44
KIT-AL 0.001 2.84 1.50 5.36 – – – –
TET2 0.004 3.43 1.48 7.96 – – – –
Abbreviations: AL, activation loop; BM, bone marrow; CI, conﬁdence interval; CR1, ﬁrst complete remission; HSCT, hematopoietic stem cell transplantation;
WCC, white cell count. KIT-ALNeg and TET2Neg was not entered into multivariate analysis, as it would mutually exclude KIT-AL and TET2. Parameters showing
statistical signiﬁcance are highlighted in bold.
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